DexCom (DXCM) stock has been in focus after Investor Day communications that many fund managers say improved sentiment, ...

If you are wondering whether DexCom stock still offers value after a choppy few years, this article walks through what the ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

In a report released on July 6, Joanne Wuensch from Citi reiterated a Buy rating on Dexcom, with a price target of $84.00. The company’s shares closed yesterday at $72.38. 55% O ...

BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...

There's been a huge drop-off in DexCom's growth rate of late, and that's a key reason investors believe that there may be a strong correlation between rising GLP-1 use and demand for CGMs. The company ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...